Introduction {#sec1_1}
============

Urothelial carcinomas (UCs) can present with diverse histological variants \[[@B1]\]. In rare instances, UCs feature neoplastic cells, distended by optically clear vacuoles that resemble lipoblasts. Under the current World Health Organization\'s classification system, this rare variant of urothelial tumor is referred to as the lipid cell variant \[[@B2]\]. Nearly all lipid cell variants of UC occur in the urinary bladder, and its pathogenesis is poorly understood \[[@B3], [@B4], [@B5], [@B6], [@B7], [@B8], [@B9], [@B10]\]. Here, we report on a case of UC with lipid cell and micropapillary variants in the ureter. We also discuss the potential molecular mechanism(s) of these variants, based on immunohistochemical evaluations.

Case Report {#sec1_2}
===========

A 64-year-old man presented with gross hematuria. Atypical urothelial cells were identified upon urinary cytology examination. Computed tomography and drip infusion/retrograde pyelography revealed a mass-occupying lesion in the left ureter, at the level of the fourth and fifth lumbar vertebrae, as well as left hydronephrosis. Upon cystoscopic evaluation, no abnormal findings were detected in the urinary bladder. Following a clinical diagnosis of left ureteral cancer, the patient underwent left nephroureterectomy.

Gross examination of the resected specimen revealed a well-demarcated papillary lesion (measuring 35 × 13 mm) in the mid-ureter. Microscopically, the major component of the tumor was a conventional, high-grade UC (fig. [1a](#F1){ref-type="fig"}). In the invasive region, however, lipid cell and micropapillary variants of UC were also observed (fig. [1b, c](#F1){ref-type="fig"}). The lipid cell variant of UC is composed of neoplastic cells, which have aberrantly arranged nuclei and optically clear cytoplasmic vacuoles that stain negatively for periodic acid Schiff and Alcian blue. The micropapillary variant of UC, on the other hand, is characterized by a small papillary architecture, typically within the tissue retraction spaces, that is reminiscent of ovarian serous papillary carcinomas. Transition between the two UC variants was also observed. The tumor invaded beyond the muscularis propria and into the periureteric fat. Metastasis to the left common iliac lymph node was detected. Metastatic lesions were composed of conventional UC only. The pathological stage was pT3 N2. Surgical margins were shown to be free from tumor.

Immunohistochemical analysis was performed, as described previously \[[@B11]\]. All components exhibited diffuse positivity for cytokeratin 7 and p53 (fig. [1d](#F1){ref-type="fig"}), but stained negatively for the S-100 protein and vimentin. Intense membranous expression of human epidermal growth factor receptor 2 (HER2) was observed in both the lipid cell and micropapillary variants of UC, whereas weak and incomplete staining was observed in most regions of the conventional UC (fig. [1e, f](#F1){ref-type="fig"}).

After surgical intervention, three cycles of methotrexate, vincristine, doxorubicin, and cisplatin were administered as adjuvant chemotherapy. Ten months following surgery, recurrence of the tumor was detected in the urinary bladder, and transurethral resection was performed. The pathological diagnosis was a high-grade, noninvasive papillary UC, with no variants of UC detected. Despite receiving intravesical instillation therapy with bacillus Calmette-Guérin, the patient experienced recurrence of the UC, in the urinary bladder and urethra, multiple times. The patient underwent total cystectomy and urethrectomy 52 months after the initial surgery. A conventional high-grade invasive UC was identified in the urethra, with no residual carcinoma detected in the urinary bladder. Seven months after cystectomy, recurrent UC was detected in the penis, and radiation therapy was performed. Unfortunately, however, the tumor continued to grow and the patient developed multiple lymph node and bone metastases. The patient died 75 months after the initial surgery.

Discussion {#sec1_3}
==========

We reported on a case of ureteral UC with lipid cell and micropapillary variants. The lipid cell variant of UC is extremely rare. Only 42 cases in the urinary bladder \[[@B3], [@B4], [@B5], [@B6], [@B7], [@B8], [@B9], [@B10]\] and a single case in the renal pelvis \[[@B3]\] have been reported in the English literature thus far. To the best of our knowledge, this represents the first published report of a lipid cell variant of UC occurring in the ureter.

The pathogenesis of the lipid cell variant of UC is poorly understood. Diffuse p53 positivity of all histological components, upon immunohistochemical analysis, is suggestive of these components harboring a *TP53* mutation, and sharing a common clonal origin. Lopez-Beltran et al. \[[@B5]\] have demonstrated that loss of heterozygosity patterns were the same for the lipid cell variant as they were for the conventional UC, further supporting this hypothesis.

Interestingly, HER2 was overexpressed in both lipid cell and micropapillary variants of UC compared to most regions of conventional UC, where HER2 expression was weak and incomplete. Micropapillary UC is characterized at the molecular level by frequent overexpression, gene amplification, and/or somatic mutation of *HER2* \[[@B12], [@B13], [@B14], [@B15]\]. De Giorgi et al. \[[@B9]\] have also reported on a case involving HER2 overexpression in the lipid cell variant of UC. Of particular note is a recent study which demonstrated that 3 out of 6 lipid cell variants of UCs were accompanied by a micropapillary variant \[[@B10]\], as also highlighted by this present case. This, therefore, suggests that there may be a close association between these two variants. It is possible that HER2 overexpression is associated with both the lipid cell and micropapillary variants of UC, and drugs targeting HER2 (e.g. trastuzumab) could be effective at treating these tumors in the future.

The lipid cell variant of UC is typically associated with advanced-stage disease and a poor prognostic outcome. Twenty-five (58%) of 43 reported cases of the lipid cell variant of UC were deceased within 5 years of receiving a diagnosis \[[@B3], [@B4], [@B5], [@B6], [@B7], [@B8], [@B9], [@B10]\]. A single published case of lipid cell variant UC, affecting the renal pelvis, also presented at an advanced stage (pT3). Despite surgical resection and treatment with chemotherapy, the patient died 8 months after being diagnosed \[[@B3]\]. In the case of our patient, he, too, had presented with advanced-stage (pT3 N2) disease, but survived for a relatively long period, i.e. 75 months after the initial surgery. Furthermore, none of the recurrent tumors was classified as a lipid cell variant of UC. Therefore, the prognostic significance of the lipid cell variant of UC is still unknown and remains to be determined.

In conclusion, we have reported a case of UC with lipid cell and micropapillary variants in the ureter. Overexpression of HER2 may be associated with both lipid cell and micropapillary variants of UC. Further research will need to be conducted in order to further elucidate the pathogenic/prognostic significance of the lipid cell variant of UC.
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![Microscopic findings of the ureteral tumor. **a** Low-power view of the lesion. The tumor is composed of a conventional UC (left) with lipid cell and micropapillary variants (right). Hematoxylin and eosin (HE) staining. Bar, 500 μm. **b** Middle-power view of the lesion. HE staining. Bar, 200 μm. **c** High-power view of the lipid cell (arrows) and micropapillary (arrowhead) variants. HE staining. Bar, 100 μm. **d** Immunostaining for p53 at the same location as depicted in **b**. All tumor components stained diffusely positive for p53. Bar, 200 μm. **e** Immunostaining for HER2. HER2 expression was weak in the conventional UC (arrows), but is overexpressed in the lipid cell and micropapillary variants. Bar, 200 μm. **f** High-power view of HER2 immunostaining in the lipid cell (arrow) and micropapillary (arrowhead) variants. Bar, 50 μm.](cro-0008-0515-g01){#F1}
